Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 71,946

Sort by:

Cells Expressing Leukocyte Antigen CD37 (Tetraspanin 26 or CD37) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Leukocyte Antigen CD37 (Tetraspanin 26 or CD37) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Leukocy...

May 2022 46 pages

Cells Expressing Mast-Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or p145 c Kit or CD117 or KIT or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Mast-Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protei...

May 2022 39 pages

Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors (Cancer-Testis Antigen 130 or Opa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen Of Melanoma or PRAME) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors (Cancer-Testis Antigen 130 or Opa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen Of Melanoma or PRAME) Drugs in...

May 2022 46 pages

Cells Expressing Melanoma Antigen Recognized By T Cells 1 (Protein Melan A or Antigen SK29 AA or Antigen LB39 AA or MART1 or MLANA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Melanoma Antigen Recognized By T Cells 1 (Protein Melan A or Antigen SK29 AA or Antigen LB39 AA or MART1 or MLANA) Drugs in Development by Therapy Areas and Indications, Stages, MoA,...

May 2022 36 pages

Cells Expressing Melanoma Associated Antigen 3 (Antigen MZ2D or Cancer-Testis Antigen 1.3 or MAGE3 Antigen or MAGEA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Melanoma Associated Antigen 3 (Antigen MZ2D or Cancer-Testis Antigen 1.3 or MAGE3 Antigen or MAGEA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule...

May 2022 41 pages

Cells Expressing Melanoma Associated Antigen 4 (Cancer-Testis Antigen 1.4 or MAGE 4 Antigen or MAGE 41 Antigen or MAGE X2 Antigen or MAGEA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Melanoma Associated Antigen 4 (Cancer-Testis Antigen 1.4 or MAGE 4 Antigen or MAGE 41 Antigen or MAGE X2 Antigen or MAGEA4) Drugs in Development by Therapy Areas and Indications, Stag...

May 2022 49 pages

Cells Expressing Mesothelin (CAK1 Antigen or Pre Pro Megakaryocyte Potentiating Factor or MSLN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Mesothelin (CAK1 Antigen or Pre Pro Megakaryocyte Potentiating Factor or MSLN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players S...

May 2022 111 pages

Cells Expressing Mucin 16 (Ovarian Cancer Related Tumor Marker CA125 or Ovarian Carcinoma Antigen CA125 or MUC16) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Mucin 16 (Ovarian Cancer Related Tumor Marker CA125 or Ovarian Carcinoma Antigen CA125 or MUC16) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 40 pages

Cells Expressing Myeloid Cell Surface Antigen CD33 (Sialic Acid Binding Ig Like Lectin 3 or gp67 or CD33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Myeloid Cell Surface Antigen CD33 (Sialic Acid Binding Ig Like Lectin 3 or gp67 or CD33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 82 pages

Cells Expressing Neural Cell Adhesion Molecule 1 (Antigen Recognized By Monoclonal Antibody 5.1H11 or CD56 or NCAM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Neural Cell Adhesion Molecule 1 (Antigen Recognized By Monoclonal Antibody 5.1H11 or CD56 or NCAM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule T...

May 2022 37 pages

Cells Expressing Neural Cell Adhesion Molecule L1 (CD171 or L1CAM) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Neural Cell Adhesion Molecule L1 (CD171 or L1CAM) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Neura...

May 2022 35 pages

Cells Expressing Phosphatidylserine Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Phosphatidylserine Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Phosphatidylserine Drugs in Developm...

May 2022 37 pages

Cells Expressing Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells...

May 2022 65 pages

Cells Expressing Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing...

May 2022 47 pages

Cells Expressing Prominin 1 (Antigen AC133 or Prominin Like Protein 1 or CD133 or PROM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Prominin 1 (Antigen AC133 or Prominin Like Protein 1 or CD133 or PROM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY...

May 2022 41 pages

Cells Expressing Prostate Stem Cell Antigen (PSCA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Prostate Stem Cell Antigen (PSCA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Prostate Stem Cell An...

May 2022 40 pages

Cells Expressing Somatostatin Receptor (SSTR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Somatostatin Receptor (SSTR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Somatostatin Receptor (SST...

May 2022 37 pages

Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Somatosta...

May 2022 38 pages

Cells Expressing Syndecan 1 (CD138 or SDC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Syndecan 1 (CD138 or SDC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Syndecan 1 (CD138 or SDC1) D...

May 2022 41 pages

Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule T...

May 2022 52 pages

Cells Expressing T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4-Leu 3 or CD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4-Leu 3 or CD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY...

May 2022 35 pages

Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1-Leu 1 or CD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1-Leu 1 or CD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cel...

May 2022 41 pages

Cells Expressing Tumor Associated Glycoprotein 72 (TAG72) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tumor Associated Glycoprotein 72 (TAG72) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Tumor Associat...

May 2022 37 pages

Cells Expressing Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMAR...

May 2022 37 pages

Cells Expressing Wilms Tumor Protein (WT33 or WT1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Wilms Tumor Protein (WT33 or WT1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Wilms Tumor Protein (...

May 2022 57 pages

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Playe...

May 2022 66 pages

Cellulitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cellulitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cellulitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides a...

May 2022 35 pages

Cerebral Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cerebral Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cerebral Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players pr...

May 2022 39 pages

Cerebral (Fatal) Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cerebral (Fatal) Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cerebral (Fatal) Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...

May 2022 35 pages

Cerebral Infarction (Brain Infarction) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cerebral Infarction (Brain Infarction) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cerebral Infarction (Brain Infarction) Drugs in Development by Stages, Ta...

May 2022 45 pages

Charcot-Marie-Tooth Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Charcot-Marie-Tooth Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Charcot-Marie-Tooth Disease Drugs in Development by Stages, Target, MoA, RoA, Molecu...

May 2022 70 pages

Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target...

May 2022 45 pages

Charcot-Marie-Tooth Disease Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Charcot-Marie-Tooth Disease Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Charcot-Marie-Tooth Disease Type II Drugs in Development by Stages, Target,...

May 2022 43 pages

Chemotherapy Effects Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Chemotherapy Effects Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chemotherapy Effects Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Ke...

May 2022 239 pages

Chemotherapy-Induced Diarrhea (CID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chemotherapy-Induced Diarrhea (CID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chemotherapy-Induced Diarrhea (CID) Drugs in Development by Stages, Target,...

May 2022 36 pages

Chemotherapy Induced Myelosuppression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chemotherapy Induced Myelosuppression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chemotherapy Induced Myelosuppression Drugs in Development by Stages, Targ...

May 2022 39 pages

Chemotherapy Induced Oral Mucositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chemotherapy Induced Oral Mucositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chemotherapy Induced Oral Mucositis Drugs in Development by Stages, Target,...

May 2022 43 pages

Chemotherapy Induced Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chemotherapy Induced Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chemotherapy Induced Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 40 pages

Childhood Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Childhood Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Childhood Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Pl...

May 2022 59 pages

Chlamydia Trachomatis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chlamydia Trachomatis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chlamydia Trachomatis Infections Drugs in Development by Stages, Target, MoA, R...

May 2022 37 pages

Cholestasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cholestasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cholestasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides...

May 2022 45 pages

Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cholinergic R...

May 2022 136 pages

Cholinergic Receptor Nicotinic Subunit (Nicotinic Acetylcholine Receptor or CHRN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cholinergic Receptor Nicotinic Subunit (Nicotinic Acetylcholine Receptor or CHRN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Choline...

May 2022 74 pages

Chordoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chordoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chordoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an ov...

May 2022 52 pages

Choroidal Neovascularization Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Choroidal Neovascularization Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Choroidal Neovascularization Drugs in Development by Stages, Target, MoA, RoA, Mole...

May 2022 67 pages

Choroideremia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Choroideremia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Choroideremia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players prov...

May 2022 37 pages

Chronic Bronchitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chronic Bronchitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chronic Bronchitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Pl...

May 2022 35 pages

Chronic Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chronic Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chronic Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players prov...

May 2022 51 pages

Chronic Cutaneous Lupus Erythematosus (CCLE) - Discoid Lupus Erythematosus (DLE) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chronic Cutaneous Lupus Erythematosus (CCLE) - Discoid Lupus Erythematosus (DLE) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chronic Cutaneous Lupus Erythem...

May 2022 40 pages

Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) Drugs...

May 2022 38 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

33% OFF on “TCR-Based Antibody a...

Discount Offer from GMD Research

280

Special Offer from MP Advisors

Special Offer on Therapy Class R...